Last update 01 Nov 2024

LHCGR

Last update 01 Nov 2024

Basic Info

Synonyms

HHG, hypergonadotropic hypogonadism, LCGR

+ [11]

Introduction

Receptor for lutropin-choriogonadotropic hormone (PubMed:11847099). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099).

Drugs associated with LHCGR

Choriogonadotropin alfa biosimilar(Livzon Pharmaceutical Group, Inc.)

Target

FSHR x LHCGR

Mechanism

FSHR agonists [+1]

Active Org.

Livzon Pharmaceutical Group, Inc.

Originator Org.

Livzon Pharmaceutical Group, Inc.

Active Indication

Infertility

Inactive Indication

Infertility, Female

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date27 Apr 2021

Merional

Target

LHCGR

Mechanism

LHCGR agonists

Active Org.

Ibsa Farmaceutici Italia Srl

Originator Org.

IBSA Institut Biochimique SA

Active Indication

Anovulation

Inactive Indication

Idiopathic Hypogonadotropic Hypogonadism [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.-

First Approval Date02 Mar 2009

Human Chorionic Gonadotrophin (Fuji Pharma)

Target

LHCGR

Mechanism

LHCGR agonists

Active Org.

Fuji Pharma Co., Ltd.

Originator Org.

Fuji Pharma Co., Ltd.

Active Indication

Abortion, Habitual [+3]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date29 Aug 2001

262

Clinical Trials associated with LHCGR

CTRI/2024/09/073446 / Not yet recruitingNot ApplicableIIT

Comparison of Clomiphene Citrate vs Human Menopausal Gonadotropin for controlled ovarian stimulation in infertile women with decreased ovarian reserve (DOR) - A randomised controlled trial - NIL

Start Date15 Sep 2024

Sponsor / Collaborator-

NCT06571214 / Not yet recruitingPhase 4IIT

An Exploratory, Randomized, Open-label, Controlled Study to Evaluate the Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.
After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.

Start Date01 Sep 2024

Sponsor / Collaborator

Nanjing University

CTR20242399 / RecruitingPhase 1

比对SJ04注射液与艾泽®在中国健康女性受试者中的药代动力学、安全性和免疫原性的Ⅰ期临床试验

[Translation] Phase I clinical trial comparing the pharmacokinetics, safety and immunogenicity of SJ04 injection and Aize® in healthy Chinese female subjects

主要目的评价SJ04注射液与艾泽®在中国健康女性受试者中单次皮下注射给药后药代动力学（PK）的相似性。次要目的评价SJ04注射液与艾泽®在中国健康女性受试者中单次皮下注射给药后的安全性和免疫原性。

[Translation]

Primary objective To evaluate the pharmacokinetic (PK) similarity between SJ04 injection and Aize® in healthy Chinese female subjects after a single subcutaneous injection. Secondary objective To evaluate the safety and immunogenicity of SJ04 injection and Aize® in healthy Chinese female subjects after a single subcutaneous injection.

Start Date12 Aug 2024

Sponsor / Collaborator

Suzhou Shengji Pharmaceutical Co Ltd

100 Clinical Results associated with LHCGR

100 Translational Medicine associated with LHCGR

0 Patents (Medical) associated with LHCGR

1,829

Literatures (Medical) associated with LHCGR

01 Dec 2024·Molecular Biology Reports

Susceptibility loci identified in Han Chinese influence genetic predisposition of PCOS in Indian women

Article

Author: Khavale, Sushma ; Joshi, Nanda ; Patil, Anushree ; Dadachanji, Roshan ; Mukherjee, Srabani

BACKGROUNDPolycystic ovary syndrome (PCOS) is a multifactorial disorder characterized by a broad spectrum of reproductive and metabolic perturbations, necessitating early timely diagnosis and management. PCOS is a multigenic disorder and ample evidence from family based, candidate gene and genome-wide association studies (GWAS) has implicated genetic factors in development and progression of PCOS. The first GWASs in Han Chinese population revealed prominent gene loci to be strong contenders in the etiopathogenesis of PCOS. However, different ethnic and geographical settings impact the genetic association pattern of PCOS.METHODS AND RESULTSIn the current case-control replication study, we have genotyped previously identified polymorphisms viz. rs2479106 and rs10818854 of DENND1A and rs13405728 of LHCGR, rs4385527 and rs3802457 of c9orf3, rs705702 of RAB5B and rs1894116 of YAP1 in control (N = 247) and PCOS (N = 504) women by Sanger sequencing, and their association with PCOS susceptibility and its related traits was investigated. We found significant association of rs4385527 of c9orf3 and rs1894116 of YAP1 with decreased and increased PCOS susceptibility respectively in non-hyperandrogenic women. Trend towards association was also noted for rs2479106 of DENND1A and rs705702 of RAB5B. Additionally, polymorphisms also showed association with metabolic and androgen related traits in both controls and hyper- and non-hyperandrogenic women with PCOS.CONCLUSIONSThus, this study shows that some, but not all polymorphisms previously identified in Han Chinese women, could contribute to the genetic pathophysiology of PCOS in Indian women, accentuating essentiality of conducting replication studies to elucidate the genetic predisposition profile of PCOS.

01 Nov 2024·The Lancet Diabetes & Endocrinology

Aberrant hormone receptors regulate a wide spectrum of endocrine tumors

Review

Author: Louiset, Estelle ; Lefebvre, Hervé ; Kamenický, Peter ; Bourdeau, Isabelle ; Chasseloup, Fanny ; Lacroix, André ; Lopez, Antoine-Guy

Aberrant G-protein coupled receptor (GPCR) expression is highly prevalent in cortisol-secreting primary bilateral macronodular adrenal hyperplasia (PBMAH) and unilateral adenomas. The aberrant expression of diverse GPCRs and their ligands play an important role in the over-function of various endocrine tumours. Examples include aberrant expression of MC2R, 5-HT4R, AVPR1A, LHCGR, and GnRHR in primary aldosteronism; GCGR, LHCGR, and 5-HT4R in phaeochromocytomas and paragangliomas; TRHR, GnRHR, GIPR, and GRP101 in pituitary somatotroph tumours; AVPR2, D2DR, and SSTR5 in pituitary corticotroph tumours; GLP1R, GIPR, and somatostatin receptors in medullary thyroid carcinoma; and SSTRs, GLP1R, and GIPR in other neuroendocrine tumours. The genetic mechanisms causing the ectopic expression of GIPR in cortisol-secreting PBMAHs and unilateral adenomas have been identified, but distinct mechanisms are implicated in other endocrine tumours. Development of functional imaging targeting aberrant GPCRs should be useful for identification and for specific therapies of this wide spectrum of tumours. The aim of this review is to show that the regulation of endocrine tumours by aberrant GPCR is not restricted to cortisol-secreting adrenal lesions, but also occurs in tumours of several other organs.

15 Oct 2024·Cells

Decreased Circulating Gonadotropin-Releasing Hormone Associated with Keratoconus.

Article

Author: Riaz, Kamran M ; Murphy, David A ; Mabry, Steve ; Cunningham, Rebecca L ; Nicholas, Sarah E ; Redden, Liam ; McKay, Tina B ; Karamichos, Dimitrios ; Choi, Alexander J ; Escandon, Paulina

Keratoconus (KC) is a corneal thinning dystrophy that leads to visual impairment. While the cause of KC remains poorly understood, changes in sex hormone levels have been correlated with KC development. This study investigated circulating gonadotropin-releasing hormone (GnRH) in control and KC subjects to determine if this master hormone regulator is linked to the KC pathology. Plasma and saliva were collected from KC subjects (n = 227 and n = 274, respectively) and non-KC controls (n = 58 and n = 101, respectively), in concert with patient demographics and clinical features. GnRH levels in both plasma and saliva were significantly lower in KC subjects compared to controls. This finding was retained in plasma when subjects were stratified based on age, sex, and KC severity. Control and KC corneal fibroblasts (HKCs) stimulated with recombinant GnRH protein in vitro revealed significantly increased luteinizing hormone receptor by HKCs and reduced expression of α-smooth muscle actin with treatment suggesting that GnRH may modulate hormonal and fibrotic responses in the KC corneal stroma. Further studies are needed to reveal the role of the hypothalamic-pituitary-gonadal axis in the onset and progression of KC and to explore this pathway as a novel therapeutic target.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

LHCGR

Basic Info

Related

Analysis